Status | Study |
Active, not recruiting |
Study Name: A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Condition: Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Date: 2016-03-07 Interventions: Drug: KRN23 Doses may be titrated to achieve the target peak serum phosphorus range |
Active, not recruiting |
Study Name: Study of KRN23 in Adult Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) Condition: Tumor Induced Osteomalacia (TIO) Epidermal Nevus Syndrome (ENS) Date: 2014-11-24 Interventions: Drug: KRN23 KRN23 is a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that b |